
Opinion|Videos|April 24, 2024
Future Management and Unmet Needs in Myelofibrosis
Author(s)Prithviraj Bose, MD
Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.
Advertisement
Case: Intermediate-Risk Primary Myelofibrosis in a 68-Year-Old Woman
Clinical Presentation:
- A 68-year-old woman presented to her physician with symptoms of mild fatigue.
- Spleen was palpable 6-7 cm below the left costal margin.
PM: No known comorbidities
Initial Clinical Workup and Diagnosis:
- NGS Testing: JAK2 V617F mutation
- Karyotype: 46XX
- BM biopsy: megakaryocyte proliferation and atypia with evidence of reticulin fibrosis
- Blood smear: leukoerythroblastosis
- Diagnosis: Primary myelofibrosis
- Risk:
- DIPSS: Intermediate-2
- Mipss70: Intermediate risk
- Lab Values
- RBC 3.40 x 1012/L
- Hgb 9.7 g/dL
- HCT 32.3%
- MCV 94 fL
- WBC 23.0 x 109/L
- PLT 450 x 109/L
- PB Blasts <1%
Initial Treatments:
- Initiated on ruxolitinib.
- The patient was not interested in transplant.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Patient Case #2: Newly Diagnosed Stage 3B NSCLC
2
Remaining Unmet Needs in Biomarker Testing in Early-stage NSCLC
3
The Targeted Pulse: Lung Cancer Advancements and FDA Decisions
4
Antitumor Activity Seen With Targeted Alpha Therapy [212Pb]VMT-α-NET in SSTR2+ NETs
5












































